Cantor Fitzgerald Maintains Overweight on Marinus Pharma, Lowers Price Target to $4

Benzinga · 10/25 16:16
Cantor Fitzgerald analyst Charles Duncan maintains Marinus Pharma (NASDAQ:MRNS) with a Overweight and lowers the price target from $13 to $4.